Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 691 to 705 of 1287 results for position

  1. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)

    Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.

  2. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    In development Reference number: GID-TA10822 Expected publication date: TBC

  3. Using our recommendations: maternity and neonatal health

    How to use NICE guidance to reduce health inequalities during and after pregnancy.

  4. Using our recommendations: cardiovascular disease

    How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).

  5. Stage 4: treatment, assessment and monitoring

    In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.

  6. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  7. Our benefits, rewards and work-life balance

    Our staff really enjoy working with us, thanks to our great package of rewards and benefits.

  8. Help us improve

    Help us improve NICE: take part in research to help us develop better products and services.

  9. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

  10. Appraisal methodology for records 1999-2013

    Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.

  11. Content assurance service

    Our content assurance service. Includes what the service offers, how to apply and pricing.

  12. Consultations

    People can comment on our guidance at specific stages in its development.

  13. Consultations

    People can comment on our guidance at specific stages in its development.

  14. Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (TA893)

    Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.